Browse by author
Lookup NU author(s): Dr Meiyi Pu,
Professor Bruce Westley,
Dr Felicity May
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Novel therapies for the treatment of colitis are required. We therefore examined the potential value of the trefoil factor family 1 (TFF1) peptide and epidermal growth factor (EGF) alone and in combination. Effects of TFF1-Cys 58±EGF on an in vitro HT29 cell wounding model of restitution showed synergistic activity when used in combination. In addition, animals had colitis induced by adding 4% dextran sulphate sodium (DSS) to the drinking water for 7 days and they also received twice daily subcutaneous injections of test peptides. Treatment with TFF1-Cys58 alone (100 μg/kg) reduced histological colitis score by 22%, but the TFF1-Ser58 variant was ineffective. In a second study, TFF1-Cys58 reduced histological colitis score by 15%, EGF (600 μg/kg) by 26%, and an additive response (42% reduction) was demonstrated when used together (P<0.01 versus either peptide given alone). Similar results were found using tissue myeloperoxidase (MPO) activity as a marker of inflammation. Where clinical risk/benefit seems justified, these initial studies suggest that combination therapy of systemic EGF and TFF peptides may prove useful for treatment of colitis in patients with disease extending beyond the reach of topical (enema) therapy. © 2004 Elsevier Inc. All rights reserved.
Author(s): FitzGerald A, Pu M, Marchbank T, Westley BR, May FEB, Boyle J, Yadollahi-Farsani M, Ghosh S, Playford R
Publication type: Article
Publication status: Published
Print publication date: 01/05/2004
ISSN (print): 0196-9781
ISSN (electronic): 1873-5169
PubMed id: 15177874
Altmetrics provided by Altmetric